Promethera extends series C on interest from Asian investors

December 16, 2016 Christoph Graener

Dr. John Tchelingerian, CEO of Promethera Biosciences, talks to Scrip senior writer Lucie Ellis on the sidelines of the 2016 BIO-Europe partnering meeting about the company’s liver disease pipeline and series C financing.
Promethera is a clinical stage pharmaceutical company developing innovative therapies for the treatment of liver diseases—its lead compound HepaStem is currently in Phase IIb for urea cycle disorders. The company also has a HepaStem/H2Stem preclinical program targeting fibrosis and NASH (non-alcoholic steatohepatitis).

Interviewer: Lucie Ellis – Senior Writer, Pharma Intelligence In Vivo/Pink Sheet/Scrip
Interviewee: Dr. John Tchelingerian – CEO, Promethera Biosciences

Previous Article
AdAlta CEO on shark antibody technology

AdAlta is developing a novel technology platform that engineers the key stability features of the antigen b...

Next Article
Deciphera CEO on tackling cancer drug resistance
Deciphera CEO on tackling cancer drug resistance

CEO Michael Taylor talks about Deciphera Pharmaceuticals’ cell-signaling technology and explains the compan...